Final Agenda

Eighth meeting of the Committee for Risk Assessment

24 November – 26 November 2009
Helsinki, Finland
24 November: starts at 9:00
26 November: ends at 16:00

Item 1 – Welcome & apologies

Item 2 – Adoption of the agenda

RAC/A/08/2009
For adoption

Item 3 – Declarations of conflicts of interest to the agenda

Item 4 – Outcome of written procedures and status report on the RAC-7 minutes

a. Outcome of written procedures and consultations
b. Status report on the RAC - 7 (Parts I & II) action points

Item 5 – Risk management options at Community level (Joint Session with SEAC)

a. Overview of relevant Community legislation
b. Assessment of RMOs
c. Examples

Item 6 – Draft opinions for CLH dossiers

a. Epoxiconazole
b. Di-tert-butyl-peroxide
c. Indium phosphide
<table>
<thead>
<tr>
<th>Item 7 – General CLH issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Feedback from the Commission on the DAT opinion</td>
</tr>
<tr>
<td>b. Feedback from the last CARACAL meeting</td>
</tr>
<tr>
<td>c. Standard phrases for opinions relating to biocide and PPP dossiers</td>
</tr>
<tr>
<td>d. RAC statement for the public consultation of TC C&amp;L substances</td>
</tr>
<tr>
<td>e. State of play of the submitted CLH dossiers</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Item 8 - Working groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discussion paper on the potential establishment of RAC working groups in the field of human health hazard assessment</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Item 9 – Request according to Art 77(3)(c) in relation to boric acid and borates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discussion following request to evaluate newly available scientific evidence on the use of boric acid and borates in photographic applications.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Item 10 – Appointment of RAC (co-) rapporteurs for intended restriction and CLH dossiers</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Appointment of (co-) rapporteurs for Annex XV restriction dossiers: phenylmercury compounds, dimethylfumarate and lead and its compounds in jewellery</td>
</tr>
<tr>
<td>b. Appointment of (co-) rapporteurs for intended CLH dossiers</td>
</tr>
</tbody>
</table>
### Item 11 – Authorisation

- **a.** Introduction to authorisation process  
  *For information*
- **b.** Preparation for handling authorisation applications  
  *RAC/08/2009/53 For information*

### Item 12 – RAC consultations on guidance documents

- **a.** Process for updating the guidance document for the preparation of a CLH dossier  
  *For information*
- **b.** Future consultations on other guidance documents  
  *For information*
- **c.** Update of the CSA and IR Guidance (Chapter 12)  
  *For consultation*

### Item 13 – Report from other ECHA bodies

- Report from meetings of the Management Board, SEAC, Forum and MSC  
  *For information*

### Item 14 – Co-operation with other Community bodies

- **a.** Report of the fifth meeting of the Chairs of EU bodies involved in risk assessment (18-19 November 2009)  
  *For information*
- **b.** Report on the issues arising during the consultation on the draft rules of procedure for co-operation between ECHA and EFSA and ACSH and SCOEL  
  *For information*

### Item 15 – Any other business

- **a.** Admission of experts supporting RAC stakeholders
- **b.** Revision of the rules for reimbursement
- **c.** Annual survey of RAC members  
  *For information*

### Item 16 – Action Points and main conclusions of RAC-8

- Table with action points and main conclusions from RAC-8  
  *For adoption*

---

*oo*